Literature DB >> 29532159

Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.

Chien-Liang Liu1,2, Po-Sheng Yang1, Ming-Nan Chien3, Yuan-Ching Chang1, Chi-Hsin Lin2,4, Shih-Ping Cheng5,6.   

Abstract

SPINT1, also known as HAI-1, is a Kunitz-type serine protease inhibitor that inhibits multiple proteases including hepatocyte growth factor (HGF) activator and matriptase. SPINT1 has been shown to modulate HGF/MET activation in certain cancer types. In the present study, we analyzed microarray datasets and found that SPINT1 was consistently upregulated in differentiated thyroid cancer. SPINT1 protein expression was investigated using tissue microarrays and independent samples of our 143 patients. Strong SPINT1 expression was observed in 61-68% of papillary thyroid cancer and 41-50% of follicular thyroid cancer. The overexpression diminished in anaplastic thyroid cancer. The SPINT1 expression in normal thyroid tissues and benign thyroid lesions was low. Furthermore, we noted that the SPINT1 expression was associated with extrathyroidal invasion, lymphovascular invasion, lymph node metastasis, advanced TNM stage, and a higher risk of recurrence in differentiated thyroid cancer. The results were in accordance with our analysis of The Cancer Genome Atlas data. In conclusion, an overexpression of SPINT1 appears to be associated with an invasive phenotype in differentiated thyroid cancer.

Entities:  

Keywords:  Hepatocyte growth factor; Invasion; Serine protease inhibitor; Thyroid cancer

Mesh:

Substances:

Year:  2018        PMID: 29532159     DOI: 10.1007/s00418-018-1660-2

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  49 in total

1.  Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer.

Authors:  Tao-Yeuan Wang; Chien-Liang Liu; Ming-Jen Chen; Jie-Jen Lee; Pou Chu Pun; Shih-Ping Cheng
Journal:  Histopathology       Date:  2014-11-25       Impact factor: 5.087

2.  Expression of 3β-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status.

Authors:  Yuan-Ching Chang; Chi-Kuan Chen; Ming-Jen Chen; Jiunn-Chang Lin; Chi-Hsin Lin; Wen-Chien Huang; Shih-Ping Cheng; Shan-Na Chen; Chien-Liang Liu
Journal:  Ann Surg Oncol       Date:  2017-07-25       Impact factor: 5.344

3.  High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.

Authors:  Salvatore Ulisse; Enke Baldini; Salvatore Sorrenti; Susi Barollo; Lucio Gnessi; Antonio Catania; Maria Rosa Pellizzo; Francesco Nardi; Caterina Mian; Enrico De Antoni; Massimino D'Armiento; Luigi Frati
Journal:  J Clin Endocrinol Metab       Date:  2010-11-24       Impact factor: 5.958

4.  Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Authors:  Michael D Oberst; Michael D Johnson; Robert B Dickson; Chen-Yong Lin; Baljit Singh; Moira Stewart; Alastair Williams; Awatif al-Nafussi; John F Smyth; Hani Gabra; Grant C Sellar
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

5.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

6.  Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

Authors:  Jung Y Kang; Marisa Dolled-Filhart; Idris Tolgay Ocal; Baljit Singh; Chen-Yong Lin; Robert B Dickson; David L Rimm; Robert L Camp
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

7.  Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.

Authors:  Yasuhiro Ito; Ayumi Akinaga; Kanako Yamanaka; Takatoshi Nakagawa; Akihiro Kondo; Robert B Dickson; Chen-Yong Lin; Akira Miyauchi; Naoyuki Taniguchi; Eiji Miyoshi
Journal:  Glycobiology       Date:  2006-02-06       Impact factor: 4.313

8.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

9.  mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch.

Authors:  Aline Hébrant; Geneviève Dom; Michael Dewaele; Guy Andry; Christophe Trésallet; Emmanuelle Leteurtre; Jacques E Dumont; Carine Maenhaut
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma.

Authors:  N J Shimwell; R T Bryan; W Wei; N D James; K K Cheng; M P Zeegers; P J Johnson; A Martin; D G Ward
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

View more
  4 in total

1.  Overexpression of Histone H3 Lysine 27 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer.

Authors:  Chia-Chi Tsai; Ming-Nan Chien; Yuan-Ching Chang; Jie-Jen Lee; Shuen-Han Dai; Shih-Ping Cheng
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

2.  Decreased expression of SPINT1-AS1 and SPINT1 mRNA might be independent unfavorable prognostic indicators in esophageal squamous cell carcinoma.

Authors:  Fang-Fang Shen; Ying Pan; Hai-Jun Yang; Jun-Kuo Li; Fang Zhao; Jing-Fen Su; Yan-Yan Li; Lin-Qiang Tian; Pan-Ting Yu; Yan-Tian Cao; Yao-Wen Zhang; Fu-You Zhou
Journal:  Onco Targets Ther       Date:  2019-06-20       Impact factor: 4.147

3.  Heme Oxygenase-1 Inhibitors Induce Cell Cycle Arrest and Suppress Tumor Growth in Thyroid Cancer Cells.

Authors:  Po-Sheng Yang; Yi-Chiung Hsu; Jie-Jen Lee; Ming-Jen Chen; Shih-Yuan Huang; Shih-Ping Cheng
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

4.  TFPI2 suppresses breast cancer progression through inhibiting TWIST-integrin α5 pathway.

Authors:  Danyi Zhao; Jingjing Qiao; Hongmei He; Jincheng Song; Shanshan Zhao; Jing Yu
Journal:  Mol Med       Date:  2020-04-05       Impact factor: 6.354

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.